78 Scientists have made significant progress in understanding chondrosarcoma, a rare and stubborn form of bone cancer that primarily affects adults over 40. The disease, which accounts for up to 30% of malignant bone tumours, is notoriously difficult to treat because it resists both chemotherapy and radiotherapy. However, new research, published in the International Journal of Molecular Sciences, offers fresh hope for those diagnosed with this slow-growing yet often deadly cancer. The latest findings point to a more complex genetic landscape than previously believed. While some subtypes of chondrosarcoma remain highly treatable with surgery, advanced cases present substantial challenges. High-grade and dedifferentiated forms of the disease can rapidly progress and spread to other parts of the body, with survival rates dropping dramatically. Dedifferentiated tumours, in particular, are linked to genetic mutations in the IDH1 and IDH2 genes, which play a role in tumour growth and resistance to treatment. A new wave of targeted therapies aims to exploit these genetic weaknesses. Drugs designed to inhibit mutated IDH enzymes are already approved for use in other cancers such as leukaemia and bile duct cancer. Trials are underway to test their effectiveness in chondrosarcoma, with early results showing promise in prolonging disease stability, especially in conventional cases of the disease. However, results have been mixed for more aggressive subtypes. Beyond targeting IDH mutations, researchers have zeroed in on other vulnerabilities. The SIRT1-HIF-2α pathway, for instance, appears crucial for tumour cell survival in harsh, nutrient-poor environments. By blocking this pathway, scientists have found that they can increase the effectiveness of chemotherapy drugs like doxorubicin. Laboratory models have shown that inhibiting SIRT1 not only slows tumour growth but may also restore sensitivity to treatments that previously failed. Immunotherapy is also being explored, particularly in cases where tumours express the DR5 receptor. A new antibody therapy, INBRX-109, has shown potential in clinical trials, controlling disease in a significant proportion of patients without the severe side effects associated with earlier immune-based treatments. Other immune strategies under investigation include CAR-T cells engineered to attack cancer cells and checkpoint inhibitors that help reactivate the body’s natural immune response. Despite these promising developments, translating them into everyday treatment remains a challenge. Patient-derived models, which mimic the real tumour environment, are still limited in number. These models are essential for accurately testing how well new therapies work. A recent breakthrough in growing organoids from patient tissue has helped address this gap, allowing for more personalised approaches to treatment testing. The complexity of chondrosarcoma means there is no one-size-fits-all solution. Yet the growing understanding of its molecular and genetic foundations is providing new avenues for intervention. As clinical trials continue, patients with advanced forms of the disease may finally see better outcomes after decades of stagnation.